Acute Leukemias: Prognostic Factors and Treatment Strategies

Front Matter....Pages I-XXVI
Front Matter....Pages 1-1
Cell Kinetics in Leukemia and Preleukemia....Pages 3-9
Acute Nonlymphocytic Leukemia in Adults: Pathophysiology, Status of Current Therapy, and New Approaches....Pages 10-14
Prognostic Significance of Chromosome Changes in Acute Leukemia....Pages 15-20
Morphological and Cytochemical Classification of Adult Acute Leukemias in Two Multicenter Studies in the Federal Republic of Germany....Pages 21-27
Front Matter....Pages 29-29
Therapeutic Strategies in Acute Myelocytic Leukemia: A Status Report of the Experience of CALGB....Pages 31-34
The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia....Pages 35-37
Long-Term Results of Two Swiss AML Studies....Pages 38-44
Prediction of Induction and Duration of Complete Remission in Acute Myelogenous Leukemia: Value of Clonogenic Cell Properties....Pages 45-49
Remission Induction and Maintenance Modalities in Acute Myeloid Leukemia: A Multicenter Randomized Study....Pages 50-56
Postinduction and Preremission Chemotherapy Alternatives for Adult AML: Three Multicenter Studies of the AML Cooperative Group....Pages 57-63
Neuraminidase-Treated Allogeneic Blasts for Maintenance in Acute Myelogenous Leukemia: Results of a Prospective Randomized Trial....Pages 64-68
Front Matter....Pages 69-69
The Childhood AML Studies BFM-78 and -83: Treatment Results and Risk Factor Analysis....Pages 71-75
Improved Treatment Results in Childhood Acute Nonlymphoblastic Leukemia with the BFM-AML Protocol 78 in a Multicenter Study in the GDR....Pages 76-82
A Comparison of Cytokinetically Based Versus Intensive Chemotherapy for Childhood Acute Myelogenous Leukemia....Pages 83-87
Postremission Induction Intensive Sequential Chemotherapy for Children with AML — Treatment Results and Prognostic Factors....Pages 88-92
Front Matter....Pages 93-93
Clinical Relevance of Blast Cell Phenotype as Determined with Monoclonal Antibodies in Acute Lymphoblastic Leukemia of Adults....Pages 95-103
Risk Groups in Adult Acute Lymphoblastic Leukemia....Pages 104-110
Prognostic Factors in Acute Lymphoblastic Leukemia in Adults: The Memorial Hospital Experience....Pages 111-124
Treatment of Adult Acute Lymphoblastic Leukemia. Preliminary Results of a Trial from the French Group....Pages 125-129
Therapy for Adolescent and Adult Acute Lymphoblastic Leukemia: Randomization of Induction and Consolidation Therapies (Preliminary Results of EORTC Study 58791)....Pages 130-136
Front Matter....Pages 137-137
Therapy Results in Five ALL-BFM Studies Since 1970: Implications of Risk Factors for Prognosis....Pages 139-146
The BFM Relapse Studies in Childhood ALL: Concepts of Two Multicenter Trials and Results after 21/2 Years....Pages 147-155
Limiting Toxicities During Intensified Remission Induction Chemotherapy for Childhood Acute Lymphocytic Leukemia....Pages 156-160
Stratification by Prognostic Factors in the Design and Analysis of Clinical Trials for Acute Lymphoblastic Leukemia....Pages 161-166
Strategies for the Treatment of Children with Acute Lymphoblastic Leukemia and Unfavorable Presenting Features....Pages 167-172
Front Matter....Pages 173-173
Infection Prevention and Immediate Antibiotic Therapy in the Neutropenic Patient....Pages 175-181
Special Aspects of Supportive Therapy in Childhood Acute Leukemias....Pages 182-187
Prevention of Infection in Patients with Acute Nonlymphocytic Leukemia by Several Drug Treatment Regimens....Pages 188-193
Front Matter....Pages 195-195
The Role of Bone Marrow Transplantation in Acute Myelogenous Leukemia....Pages 197-203
Allogeneic Marrow Transplantation for Treatment of Leukemia: Results of the Munich Cooperative Group....Pages 204-212
Bone Marrow Transplantation in Acute Leukemia....Pages 213-216
Bone Marrow Transplantation in Childhood Leukemia in West Germany....Pages 217-225
Allogeneic, Syngeneic, and Autologous Bone Marrow Transplantation in the Acute Leukemias — Baltimore Experience....Pages 226-232
Treatment of Patients with Acute Myeloid Leukemia in First Remission with Marrow Ablative Therapy and Autologous Bone Marrow Transplantation....Pages 233-236
Front Matter....Pages 237-237
Modification of tRNA and Its Applicability for the Assessment of Prognosis, State of Differentiation, and Clonality in Human Leukemias and Lymphomas....Pages 241-250
Immunoglobulin and T Cell Receptor Gene Rearrangements in Acute Leukemias....Pages 251-255
Abnormal Production and Release of Ferritin by Immature Myeloid Cells in Leukemia....Pages 256-260
Induction of Early Myeloperoxidase in Acute Unclassified Leukemia....Pages 261-264
Abnormal Marker Expression in Acute Leukemia (AL) Characterized by Monoclonal Antibodies and Flow Cytometry....Pages 265-270
Urinary GP41 Excretion in Patients with Acute Leukemias Treated with Intensive Induction Polychemotherapy....Pages 271-277
Front Matter....Pages 237-237
Toxicity and Mutagenicity of 6 Anti-Cancer Drugs in Chinese Hamster Cells Co-Cultured with Rat Hepatocytes....Pages 278-282
Pharmacokinetics of Daunorubicin as a Determinant of Response in Acute Myeloid Leukemia....Pages 283-287
Pharmacokinetic Study of Cytosine Arabinoside in Patients with Acute Myelogeneous Leukemia....Pages 288-292
Pharmacokinetics of Oral Methotrexate in Bone Marrow During Maintenance Treatment of Childhood Acute Lymphocytic Leukemia....Pages 293-297
Determination of the Cellular Uptake of Daunorubicin in Human Leukemia in vivo: Method of Examination and First Results....Pages 298-301
Cytoskeletal Organization in Acute Leukemias....Pages 302-307
Pitfalls in the Evaluation of Prognostic Factors....Pages 308-312
Low-Dose Ara-C in Myelodysplastic Syndromes and Acute Nonlymphoid Leukemia. Experience with Seven Patients....Pages 315-321
Low-Dose Cytosine Arabinoside in Patients with Acute Myeloblastic Leukemia and Myelodysplastic Syndrome....Pages 322-325
Low-Dose Ara-C Treatment in Elderly Patients with Acute Myeloblastic Leukemia....Pages 326-329
Acute Leukaemia in the Elderly, Remission Induction Versus Palliative Therapy....Pages 330-332
The Use of Amsacrine plus Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Nonlymphocytic Leukemia....Pages 333-335
Phase I/II Trial of High-Dose Cytosine Arabinoside and Mitoxantrone in Adult Refractory Acute Myeloid Leukemia....Pages 336-338
Mitoxantrone and VP-16 in Refractory Acute Myelogenous Leukemia....Pages 339-342
4-Demethoxydaunorubicin (Idarubicin) in Relapsed and Refractory Acute Myeloid Leukemia....Pages 343-345
Intensive Induction and Consolidation Chemotherapy for Adults and Children with Acute Myeloid Leukaemia (AML) Joint AML Trial 1982–1985....Pages 346-351
Remission Induction with Cytarabine and Daunorubicin With or Without 6-Thioguanine in Adult Patients With Acute Myelocytic Leukemia....Pages 352-355
Contribution of Clonogenic Leukemic Cell Characteristics to Therapy Outcome in Patients With Acute Myeloblastic Leukemia....Pages 356-360
Expression of CD-15 Antigen on Leukemic Cells — A New Prognostic Factor for Ability to Achieve Complete Remission and for Survival in ANLL....Pages 361-364
Prognostic Significance of Morphologic and Cytogenetic Findings for Progression in Myelodysplastic Syndromes....Pages 365-368
Front Matter....Pages 237-237
Analysis of Prognostic Factors in Acute Leukemias in Adults....Pages 369-372
Acute Myelocytic Leukemia in Adults: A Long-Term Analysis....Pages 373-375
Prognostic Factors in Acute Myelogenous Leukemia....Pages 376-379
Serum Zinc and Copper as Prognostic Factors in Acute Nonlymphocytic Leukemia....Pages 380-384
Immunological Monitoring in Remission Acute Myeloid Leukemia During Maintenance Therapy....Pages 385-386
Treatment of Childhood Acute Nonlymphocytic Leukemia with Individually Scheduled High Doses of Cytarabine: Preliminary Results of Study ANLL-82 of the Dutch Childhood Leukemia Study Group (DCLSG)....Pages 389-392
Aclacinomycin-A in the Induction Treatment of Childhood Acute Myelogenous Leukemia....Pages 393-398
High-Dose Cytosine Arabinoside and Retinol in the Treatment of Acute Myelogenous Leukemia in Childhood....Pages 399-402
CHOP Treatment of Childhood Acute Myelogenous Leukemia with Monocytic Differentiation: A Report on Five Cases....Pages 403-405
Effective Remission Induction in Children with Recurrent Acute Myeloid Leukemia by mAMSA, Ara-C, and VP 16....Pages 406-409
Alteration of Blast Phenotype after Low-Dose Cytarabine in Children with Acute Myeloid Leukemia....Pages 410-412
Biphenotypic Leukemia in Childhood: Presentation of Five Cases....Pages 413-417
Surface Marker Analysis by Monoclonal Antibodies: A Valuable Technique in Childhood Acute Myeloid Leukemia....Pages 418-422
Infant Leukemia: A Single Pattern of Nonlymphocytic Leukemia?....Pages 423-423
Growth of Children with Acute Lymphocytic Leukemia: Preliminary Results....Pages 427-431
Two Unexpected Courses in Four Children with Lymphoblastic Leukemia of B-Cell Type (B-ALL)....Pages 432-436
Progress in Treatment of Children with non-Hodgkin Lymphoma: A Report of the Polish Leukemia and Lymphoma Study Group....Pages 437-443
Addition of Rubidomycin to Induction Treatment with Vincristine, Prednisone, and l -Asparaginase in Standard-Risk Childhood Acute Lymphocytic Leukemia (Study ALL V): A Report on Behalf of the Dutch Childhood Leukemia Study Group....Pages 444-447
Medical Research Council Childhood Leukaemia Trial VIII Compared with Trials II–VII: Lessons for Future Management....Pages 448-455
Early Intensification Therapy in High-Risk Childhood Acute Lymphocytic Leukemia: Lack of Benefit from High-Dose Methotrexate....Pages 456-460
Front Matter....Pages 237-237
Intermediate-Risk Childhood Acute Lymphoblastic Leukemias: Amsacrine + Cytosine Arabinoside Versus Intermediate-Dose Methotrexate for Consolidation, and 6-Mercaptopurine + Methotrexate + Vincristine Versus Monthly Pulses for Maintenance....Pages 461-465
Treatment of Acute Lymphoblastic Leukemia in Children with the BFM Protocol: A Cooperative Study and Analysis of Prognostic Factors....Pages 466-470
Results of Acute Lymphoblastic Leukemia Therapy in Childhood with a Modified BFM Protocol in a Multicenter Study in the German Democratic Republic....Pages 471-479
Intensive Therapy in Childhood Acute Lymphoblastic Leukemia: A Report from the Polish Children’s Leukemia and Lymphoma Study Group After 11 Years....Pages 480-482
Treatment of Standard- and High-Risk Childhood Acute Lymphoblastic Leukaemia with Two CNS Prophylaxis Regimens....Pages 483-492
Aggressive Combination Chemotherapy of Bone Marrow Relapse in Childhood Acute Lymphoblastic Leukemia Containing Aclacinomycin-A: A Multicentric Trial....Pages 493-496
Prognostic Meaning of Chromosome Aberrations in Acute Lymphocytic Leukemia and Acute Nonlymphocytic Leukemia Patients of the BFM Study Group....Pages 497-503
Karyotype, Immunophenotype, and Clinical Outcome: Correlations in Childhood Acute Lymphoblastic Leukemia....Pages 504-508
DNA Aneuploidy in Children with Relapsed Acute Lymhoblastic Leukemia as Measured by Flow Cytometry....Pages 509-512
Hyperdiploid Childhood Acute Lymphocytic Leukemia: Cellular Properties and Prognostic Implications....Pages 513-516
Intensive Care Therapy for Patients with Hematological Diseases....Pages 519-523
The Problem of Early Death in Childhood AML....Pages 524-529
Passive and Active Anti-Hepatitis B Immunization of Children with Hematological Malignancies....Pages 530-534
Increased Awareness of Aspergillosis in Acute Leukemia Patients....Pages 535-537
Cytomegalovirus Hyperimmunoglobulin and Substitution with Blood Products from Antibody-Negative Donors. A Pilot Study in Bone Marrow Transplant Recipients....Pages 538-540
Prophylactic Application of an Anti-Cytomegalovirus Hyperimmunoglobulin in Allogeneic Bone Marrow Transplant Recipients....Pages 541-544
Incidence and Treatment of Fungal Infections in Neutropenic Patients....Pages 545-546
First Experiences with a Permanent Catheter System in Acute Leukemia....Pages 547-550
On the Fate of Leukemic Cells Infused with the Autologous Marrow Graft....Pages 553-559
Hematological Reconstitution After Autologous Peripheral Blood Transplantation....Pages 560-562
Front Matter....Pages 237-237
Depletion of T Cells from Bone Marrow Grafts with Soybean Agglutinin and Sheep Red Blood Cells for Prevention of Graft-Versus-Host Disease....Pages 563-566
Bone Marrow Transplantation for Chronic Granulocytic Leukemia: Results of the French Cooperative Group (GEGMO)....Pages 567-570
An HLA Lost Mutation May Lead to Leukemic Relapse of Recipient Type Six Years After Bone Marrow Transplantation....Pages 571-573
Toxoplasmosis After Bone Marrow Transplantation....Pages 574-578
Back Matter....Pages 579-586